The third webinar* in the COVID-19 monthly briefing series was designed to provide insight from life sciences thought-leaders and to generate discussion on issues that pharma and biotech co
Bavarian Nordic is preparing to file for regulatory approval of a vaccine against chikungunya virus after its CHIKV VLP candidate showed protective efficacy in a second ph
To improve trial recruitment, engagement, and retention, and to increase the likelihood that trials reflect what matters most to patients, regulatory authorities increasingly point to metho